Tumor Characteristics and Treatment Responsiveness in Pembrolizumab-Treated Non-Small Cell Lung Carcinoma
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Patients and Tissue Samples
2.2. Assessment of Tumor Histology and Molecular Studies
2.3. Tumor PD-L1 Scoring
2.4. Efficacy Assessment
2.5. Statistical Analysis
3. Results
3.1. Patient Characteristics
3.2. Treatment Outcome
3.3. Tumor-Infiltrating Lymphocytes and CD8+ Lymphocytes
3.4. PD-L1 Expression Status
3.5. Somatic Molecular Alterations
3.6. Histopathological Assessment of Tumor Characteristics including Tumor Cellularity and Tumor-Infiltrating Lymphocytes
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Siegel, R.L.; Miller, K.D.; Wagle, N.S.; Jemal, A. Cancer statistics, 2023. CA A Cancer J. Clin. 2023, 73, 17–48. [Google Scholar] [CrossRef] [PubMed]
- Schabath, M.B.; Cote, M.L. Cancer Progress and Priorities: Lung Cancer. Cancer Epidemiol. Biomark. Prev. 2019, 28, 1563–1579. [Google Scholar] [CrossRef] [PubMed]
- Wakelee, H.; Kelly, K.; Edelman, M.J. 50 Years of Progress in the Systemic Therapy of Non–Small Cell Lung Cancer. Am. Soc. Clin. Oncol. Educ. Book 2014, 34, 177–189. [Google Scholar] [CrossRef] [PubMed]
- Steven, A.; Fisher, S.A.; Robinson, B.W. Immunotherapy for lung cancer. Respirology 2016, 21, 821–833. [Google Scholar] [CrossRef] [PubMed]
- Somasundaram, A.; Burns, T.F. The next generation of immunotherapy: Keeping lung cancer in check. J. Hematol. Oncol. 2017, 10, 87. [Google Scholar] [CrossRef] [PubMed]
- Bremnes, R.M.; Al-Shibli, K.; Donnem, T.; Sirera, R.; Al-Saad, S.; Andersen, S.; Stenvold, H.; Camps, C.; Busund, L.T. The Role of Tumor-Infiltrating Immune Cells and Chronic Inflammation at the Tumor Site on Cancer Development, Progression, and Prognosis: Emphasis on Non-small Cell Lung Cancer. J. Thorac. Oncol. 2011, 6, 824–833. [Google Scholar] [CrossRef]
- Lee, J.; Kefford, R.; Carlino, M. PD-1 and PD-L1 inhibitors in melanoma treatment: Past success, present application, and future challenges. Immunotherapy 2016, 8, 733–746. [Google Scholar] [CrossRef]
- Gandhi, L.; Rodríguez-Abreu, D.; Gadgeel, S.; Esteban, E.; Felip, E.; De Angelis, F.; Domine, M.; Clingan, P.; Hochmair, M.J.; Powell, S.F.; et al. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2018, 378, 2078–2092. [Google Scholar] [CrossRef]
- Reck, M.; Mok, T.S.K.; Nishio, M.; Jotte, R.M.; Cappuzzo, F.; Orlandi, F.; Stroyakovskiy, D.; Nogami, N.; Rodríguez-Abreu, D.; Moro-Sibilot, D.; et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): Key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir. Med. 2019, 7, 387–401. [Google Scholar] [CrossRef]
- Felip, E.; Altorki, N.; Zhou, C.; Csőszi, T.; Vynnychenko, I.; Goloborodko, O.; Luft, A.; Akopov, A.; Martinez-Marti, A.; Kenmotsu, H.; et al. IMpower010 Investigators. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): A randomised, multicentre, open-label, phase 3 trial. Lancet 2021, 398, 1344–1357. [Google Scholar] [CrossRef] [PubMed]
- O’Brien, M.; Paz-Ares, L.; Marreaud, S.; Dafni, U.; Oselin, K.; Havel, L.; Esteban, E.; Isla, D.; Martinez-Marti, A.; Faehling, M.; et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): An interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022, 23, 1274–1286. [Google Scholar] [CrossRef]
- Forde, P.M.; Spicer, J.; Lu, S.; Provencio, M.; Mitsudomi, T.; Awad, M.M.; Felip, E.; Broderick, S.R.; Brahmer, J.R.; Swanson, S.J.; et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N. Engl. J. Med. 2022, 386, 1973–1985. [Google Scholar] [CrossRef] [PubMed]
- Antonia, S.J.; Villegas, A.; Daniel, D.; Vicente, D.; Murakami, S.; Hui, R.; Yokoi, T.; Chiappori, A.; Lee, K.H.; De Wit, M.; et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2017, 377, 1919–1929. [Google Scholar] [CrossRef] [PubMed]
- Pai-Scherf, L.; Blumenthal, G.M.; Li, H.; Subramaniam, S.; Mishra-Kalyani, P.S.; He, K.; Zhao, H.; Yu, J.; Paciga, M.; Goldberg, K.B.; et al. FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond. Oncologist 2017, 22, 1392–1399. [Google Scholar] [CrossRef] [PubMed]
- Garinet, S.; Wang, P.; Mansuet-Lupo, A.; Fournel, L.; Wislez, M.; Blons, H. Updated Prognostic Factors in Localized NSCLC. Cancers 2022, 14, 1400. [Google Scholar] [CrossRef] [PubMed]
- Pu, X.; Wu, L.; Su, D.; Mao, W.; Fang, B. Immunotherapy for non-small cell lung cancers: Biomarkers for predicting responses and strategies to overcome resistance. BMC Cancer 2018, 18, 1082. [Google Scholar] [CrossRef] [PubMed]
- Hwang, S.; Kwon, A.-Y.; Jeong, J.-Y.; Kim, S.; Kang, H.; Park, J.; Kim, J.-H.; Han, O.J.; Lim, S.M.; An, H.J. Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer. Sci. Rep. 2020, 10, 643. [Google Scholar] [CrossRef] [PubMed]
- Kaira, K.; Yamaguchi, O.; Kawasaki, T.; Hashimoto, K.; Miura, Y.; Shiono, A.; Mouri, A.; Imai, H.; Kobayashi, K.; Yasuda, M.; et al. Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer. Discov. Oncol. 2023, 14, 6. [Google Scholar] [CrossRef]
- De Marchi, P.; Leal, L.F.; da Silva, V.D.; da Silva, E.C.A.; de Lima, V.C.C.; Reis, R.M. PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC). J. Clin. Pathol. 2021, 74, 735–740. [Google Scholar] [CrossRef]
- Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, L.H.; Sargent, D.; Ford, R.; Dancey, J.; Arbuck, S.; Gwyther, S.; Mooney, M.; et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 2009, 45, 228–247. [Google Scholar] [CrossRef]
- Xi, K.X.; Wen, Y.S.; Zhu, C.M.; Yu, X.Y.; Qin, R.Q.; Zhang, X.W.; Lin, Y.B.; Rong, T.H.; Wang, W.D.; Chen, Y.Q.; et al. Tumor-stroma ratio (TSR) in non-small cell lung cancer (NSCLC) patients after lung resection is a prognostic factor for survival. J. Thorac. Dis. 2017, 9, 4017–4026. [Google Scholar] [CrossRef] [PubMed]
- Zhang, T.; Xu, J.; Shen, H.; Dong, W.; Ni, Y.; Du, J. Tumor-stroma ratio is an independent predictor for survival in NSCLC. Int. J. Clin. Exp. Pathol. 2015, 8, 11348–11355. [Google Scholar] [PubMed]
- Soo, R.A.; Chen, Z.; Yan Teng, R.S.; Tan, H.L.; Iacopetta, B.; Tai, B.C.; Soong, R. Prognostic significance of immune cells in non-small cell lung cancer: Meta-analysis. Oncotarget 2018, 9, 24801. [Google Scholar] [CrossRef] [PubMed]
- Hashemi, S.; Fransen, M.F.; Niemeijer, A.; Ben Taleb, N.; Houda, I.; Veltman, J.; Becker-Commissaris, A.; Daniels, H.; Crombag, L.; Radonic, T.; et al. Surprising impact of stromal TIL’s on immunotherapy efficacy in a real-world lung cancer study. Lung Cancer 2021, 153, 81–89. [Google Scholar] [CrossRef] [PubMed]
- Li, F.; Li, C.; Cai, X.; Xie, Z.; Zhou, L.; Cheng, B.; Zhong, R.; Xiong, S.; Li, J.; Chen, Z.; et al. The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis. EClinicalMedicine 2021, 41, 101134. [Google Scholar] [CrossRef] [PubMed]
- Carbone, D.P.; Gandara, D.R.; Antonia, S.J.; Zielinski, C.; Paz-Ares, L. Non–Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. J. Thorac. Oncol. 2015, 10, 974–984. [Google Scholar] [CrossRef]
- Sundar, R.; Cho, B.-C.; Brahmer, J.R.; Soo, R.A. Nivolumab in NSCLC: Latest evidence and clinical potential. Ther. Adv. Med. Oncol. 2015, 7, 85–96. [Google Scholar] [CrossRef]
- Reck, M.; Rodríguez-Abreu, D.; Robinson, A.G.; Hui, R.; Csőszi, T.; Fülöp, A.; Gottfried, M.; Peled, N.; Tafreshi, A.; Cuffe, S.; et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2016, 375, 1823–1833. [Google Scholar] [CrossRef]
- Aguilar, E.J.; Ricciuti, B.; Gainor, J.F.; Kehl, K.L.; Kravets, S.; Dahlberg, S.; Nishino, M.; Sholl, L.M.; Adeni, A.; Subegdjo, S.; et al. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann. Oncol. 2019, 30, 1653–1659. [Google Scholar] [CrossRef]
- Udall, M.; Rizzo, M.; Kenny, J.; Doherty, J.; Dahm, S.A.; Robbins, P.; Faulkner, E. PD-L1 diagnostic tests: A systematic literature review of scoring algorithms and test-validation metrics. Diagn. Pathol. 2018, 13, 12. [Google Scholar] [CrossRef]
- Wang, Y.; Tong, Z.; Zhang, W.; Zhang, W.; Buzdin, A.; Mu, X.; Yan, Q.; Zhao, X.; Chang, H.H.; Duhon, M.; et al. FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients. Front. Oncol. 2021, 11, 683419. [Google Scholar] [CrossRef] [PubMed]
Characteristic | Overall, n = 84 1 | Responsive, n = 42 1 | Stable, N = 23 1 | Progressive, n = 19 1 | p-Value 2 |
---|---|---|---|---|---|
Age | 65 (61, 74) | 68 (62, 76) | 65 (60, 71) | 64 (57, 70) | 0.2 |
Gender | 0.6 | ||||
Female | 48 (57%) | 23 (55%) | 15 (65%) | 10 (53%) | |
Male | 36 (43%) | 19 (45%) | 8 (35%) | 9 (47%) | |
Diagnosis | 0.3 | ||||
Adenocarcinoma | 51 (61%) | 26 (63%) | 15 (65%) | 10 (53%) | |
Squamous cell carcinoma | 18 (22%) | 7 (17%) | 6 (26%) | 5 (26%) | |
Adenosquamous carcinoma | 1 (1.2%) | 0 (0%) | 1 (4.3%) | 0 (0%) | |
NSCLC | 13 (16%) | 8 (20%) | 1 (4.3%) | 4 (21%) | |
Smoking | 0.7 | ||||
Current | 27 (33%) | 12 (30%) | 9 (41%) | 6 (32%) | |
Former | 46 (57%) | 22 (55%) | 12 (55%) | 12 (63%) | |
Never | 8 (9.9%) | 6 (15%) | 1 (4.5%) | 1 (5.3%) | |
Second Malignancy | 11 (13%) | 6 (14%) | 4 (17%) | 1 (5.3%) | 0.5 |
Group | Overall Mutation (n) | TP53 Mutation (n) | KRAS Mutation (n) |
---|---|---|---|
RG (n = 42) | 40 | 24 | 19 |
SD (n = 23) | 22 | 7 | 11 |
PD (n = 19) | 17 | 11 | 8 |
Total (n = 84) | 79 | 42 | 38 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Li, H.; Shyam Sunder, S.; Jatwani, K.; Bae, Y.; Deng, L.; Liu, Q.; Dy, G.K.; Pokharel, S. Tumor Characteristics and Treatment Responsiveness in Pembrolizumab-Treated Non-Small Cell Lung Carcinoma. Cancers 2024, 16, 744. https://doi.org/10.3390/cancers16040744
Li H, Shyam Sunder S, Jatwani K, Bae Y, Deng L, Liu Q, Dy GK, Pokharel S. Tumor Characteristics and Treatment Responsiveness in Pembrolizumab-Treated Non-Small Cell Lung Carcinoma. Cancers. 2024; 16(4):744. https://doi.org/10.3390/cancers16040744
Chicago/Turabian StyleLi, Haiyan, Sunitha Shyam Sunder, Karan Jatwani, Yongho Bae, Lei Deng, Qian Liu, Grace K. Dy, and Saraswati Pokharel. 2024. "Tumor Characteristics and Treatment Responsiveness in Pembrolizumab-Treated Non-Small Cell Lung Carcinoma" Cancers 16, no. 4: 744. https://doi.org/10.3390/cancers16040744
APA StyleLi, H., Shyam Sunder, S., Jatwani, K., Bae, Y., Deng, L., Liu, Q., Dy, G. K., & Pokharel, S. (2024). Tumor Characteristics and Treatment Responsiveness in Pembrolizumab-Treated Non-Small Cell Lung Carcinoma. Cancers, 16(4), 744. https://doi.org/10.3390/cancers16040744